Currently, approximately 90% of insulin users in the United States use analogue insulins, which were first introduced to the US market in 1996 and rapidly became widely used despite higher costs, because of effective marketing and studies indicating a lower rate of mild hypoglycemia.1,10,11 Although hypoglycemia rates related to various types of insulin have been extensively investigated, the effects of human compared with analogue insulins on cardiovascular events and mortality have received much less attention. This evidence concerns the gene INS and Hypoglycemia.